Genmab A/S (OTCMKTS:GNMSF) Short Interest Down 20.5% in January

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 80,900 shares, a drop of 20.5% from the January 15th total of 101,800 shares. Based on an average daily volume of 21,300 shares, the short-interest ratio is presently 3.8 days.

Genmab A/S Trading Up 2.5 %

Shares of GNMSF stock traded up $5.17 on Wednesday, hitting $216.14. 512 shares of the stock were exchanged, compared to its average volume of 6,697. The firm's 50 day moving average is $206.14 and its two-hundred day moving average is $228.78. Genmab A/S has a one year low of $186.61 and a one year high of $323.02. The firm has a market capitalization of $14.28 billion, a PE ratio of 12.34 and a beta of 1.04.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a return on equity of 19.75%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.